Recruiting studies: Bone Marrow Transplantation

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Activity Levels in Bone Marrow Transplant Patients
Phase N/A · 1 location(s) · Michael Tomasson · NCT04115241 A Phase 1/3 Study of T-Cell Receptor Engineered Donor T Cells in Subjects Undergoing Allogeneic Peripheral Blood Stem Ce
Phase 1 · 21 location(s) · TScan Therapeutics, Inc. · NCT05473910 Thiotepa-Containing Conditioning Regimen for Allogeneic HSCT in Chronic Myelomonocytic Leukemia
NA · 1 location(s) · Peking University People's Hospital · NCT07588594 MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing
NA · 1 location(s) · Medical College of Wisconsin · NCT05794880 Methods of T Cell Depletion Trial (MoTD)
Phase 2 · 17 location(s) · University of Birmingham · NCT04888741 Haplo-Cord HSCT for AML/MDS
NA · 4 location(s) · Fujian Medical University Union Hospital · NCT07588360 BMT-CARE: Psychosocial Intervention for Transplant Caregivers
NA · 3 location(s) · Massachusetts General Hospital · NCT06472089 The HOPE Biobank Resource (BMT CTN 2402 HOPE)
Phase N/A · 6 location(s) · Medical College of Wisconsin · NCT07227155 Ruxolitinib Before, During and After Hematopoietic Cell Transplant in Older Patients With Myelofibrosis and Myelodysplas
Phase 2 · 1 location(s) · Fred Hutchinson Cancer Center · NCT07228624 oGVHD After Bone Marrow Transplantation: a Territory-wide Cohort
Phase N/A · 1 location(s) · The University of Hong Kong · NCT05170347 Compassionate Access of the Miltenyi Device for CD34+ Cell Selection
NA · 1 location(s) · M.D. Anderson Cancer Center · NCT02438904 AlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion
Phase 2 · 1 location(s) · Mitchell Cairo · NCT04099966 Molecular Mechanisms of Disease Relapse After Allogenic Stem Cell Transplantation in MDS Patients
NA · 7 location(s) · Gruppo Italiano Malattie EMatologiche dell'Adulto · NCT04587856 Orphan Indications for CD19 Redirected Autologous T Cells
Phase 2 · 1 location(s) · Stephan Grupp MD PhD · NCT04276870 Momelotinib During and After HCT in Myelofibrosis
Phase 1 · 1 location(s) · Massachusetts General Hospital · NCT07104799 Trial for Patients w/ Advanced Hematologic Malignancies Undergoing Allogeneic HCT
Phase 1 · 1 location(s) · Stanford University · NCT06551584 Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Foll
Phase 1/Phase 2 · 1 location(s) · National Cancer Institute (NCI) · NCT05470491 Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyc
Phase 1 · 2 location(s) · University of Kansas Medical Center · NCT03533816 A Novel Conditioning Regimen for Haplo-HSCT in Older Patients With SAA
Phase N/A · 1 location(s) · Peking University People's Hospital · NCT07586735 IS-free Treg HaploHCT
Phase 1 · 1 location(s) · Dana-Farber Cancer Institute · NCT04678401 Vitamin A and D Supplementation in Allogeneic HCT
Phase 2 · 1 location(s) · St. Petersburg State Pavlov Medical University · NCT06508099 Safety and Feasibility of Sulforaphane to Promote Early Haematopoietic Recovery After Cord Blood Transplantation
NA · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT07297576 Unrelated Umbilical Cord Blood Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS Using CordIn(TM), Umbilic
Phase 1/Phase 2 · 1 location(s) · National Heart, Lung, and Blood Institute (NHLBI) · NCT03173937 Emapalumab With Post-Transplant Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Graft-versu
Phase 1 · 1 location(s) · City of Hope Medical Center · NCT06996119 Post Transplant Cyclophosphamide in Matched Unrelated Donor Stem Cell Transplantation for Hematological Malignancies
Phase 2/Phase 3 · 1 location(s) · Hospital Israelita Albert Einstein · NCT03818334 Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
Phase 2 · 1 location(s) · Masonic Cancer Center, University of Minnesota · NCT03314974 Natural History Study to Determine Drug Metabolism Phenotype and Appropriate Germline Source DNA in Patients Undergoing
Phase N/A · 1 location(s) · National Cancer Institute (NCI) · NCT06856226 Multi-omic Characterization of Pediatric and Adult Patients Undergoing Hematopoietic Stem Cell Transplantation and Advan
NA · 1 location(s) · IRCCS Azienda Ospedaliero-Universitaria di Bologna · NCT07464483 MAGIC Ruxolitinib for aGVHD
Phase 2 · 14 location(s) · John Levine · NCT06936566 CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relap
Phase 1 · 1 location(s) · Fred Hutchinson Cancer Center · NCT04375631

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.